DK2851084T3 - Modulation af Vps10p-domæne-receptorer til behandlingen af kardiovaskulær sygdom - Google Patents

Modulation af Vps10p-domæne-receptorer til behandlingen af kardiovaskulær sygdom Download PDF

Info

Publication number
DK2851084T3
DK2851084T3 DK14192407.6T DK14192407T DK2851084T3 DK 2851084 T3 DK2851084 T3 DK 2851084T3 DK 14192407 T DK14192407 T DK 14192407T DK 2851084 T3 DK2851084 T3 DK 2851084T3
Authority
DK
Denmark
Prior art keywords
leu
ser
gly
val
ala
Prior art date
Application number
DK14192407.6T
Other languages
English (en)
Inventor
Anders Nykjaer
Mads Fuglsang Kjølby
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Application granted granted Critical
Publication of DK2851084T3 publication Critical patent/DK2851084T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Claims (8)

  1. J.
    1. Antistof til anvendelse i en fremgangsmåde til behandling og/eller forebyggelse af abnorme plasma-lipidkoncentrationer hos et dyr, hvor nævnte antistof er en antagonist og nævnte antistof er i stand til at binde til en receptor af Sortilin, for derved at inhibere aktiviteten af nævnte Sortilin-receptor.
  2. 2. Antistoffet ifølge krav 1, hvor nævnte antistof er i stand til at inhibere binding af ApoB til nævnte Sortilin-receptor.
  3. 3. Antistoffet ifølge et hvilket som helst af de foregående krav, hvor dyret er et menneske.
  4. 4. Antistoffet ifølge krav 1, hvor nævnte antistof er valgt fra gruppen bestående af: polyklonale antistoffer, monoklonale antistoffer, humaniserede antistoffer, enkelt-kædede antistoffer, rekombinante antistoffer.
  5. 5. Antistoffet ifølge et hvilket som helst af kravene 1-6, hvor antistoffet er rettet mod den ekstracellulære del af Sortilin.
  6. 6. Antagonisten ifølge et hvilket som helst af de foregående krav, hvor antagonisten binder en aminosyrerest af bindingsstedet omfattende aminosyrerester R325, S316, Y351, 1353, K260, 1327, F314, F350 til M363, S305, F306, T398 til G400, I303-G309, Q349-A356, Y395 og T402 af SEQ ID NO. 1.
  7. 7. Antagonisten ifølge et hvilket som helst af de foregående krav, hvor antagonisten binder en aminosyrerest af bindingsstedet omfattende aminosyrerester L572, L114, V112, R109 til Sill, S115 til G118, T570, G571, W586, W597, T168-I174, L572, A573 og S584 til F588 af SEQ ID NO. 1.
  8. 8. Anvendelsen ifølge krav 1, hvor abnorme plasmalipidkoncentrationer er i primær hyperlipoproteinæmi, kombineret hyperlipidæmi, endogen Hyperlipæmi, familiær hypertriglyceridæmi, atherosklerose, hjerneblødning (slagtilfælde), cerebrovaskulær sygdom, koronarsklerose, hyperkolesterolæmi, hyperlipidæmi, myokardieinfarkt (hjerteanfald) og veneblodprop.
DK14192407.6T 2008-05-22 2009-05-20 Modulation af Vps10p-domæne-receptorer til behandlingen af kardiovaskulær sygdom DK2851084T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5538508P 2008-05-22 2008-05-22
DKPA200800711 2008-05-22
EP09749511.3A EP2282728B1 (en) 2008-05-22 2009-05-20 Modulation of the Vps10p-domain receptors.

Publications (1)

Publication Number Publication Date
DK2851084T3 true DK2851084T3 (da) 2018-07-30

Family

ID=41016888

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14192407.6T DK2851084T3 (da) 2008-05-22 2009-05-20 Modulation af Vps10p-domæne-receptorer til behandlingen af kardiovaskulær sygdom
DK09749511.3T DK2282728T3 (da) 2008-05-22 2009-05-20 Modulation at Vps10p-domæne-receptorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09749511.3T DK2282728T3 (da) 2008-05-22 2009-05-20 Modulation at Vps10p-domæne-receptorer

Country Status (6)

Country Link
US (2) US9084745B2 (da)
EP (2) EP2282728B1 (da)
DK (2) DK2851084T3 (da)
ES (2) ES2680222T3 (da)
HK (1) HK1208802A1 (da)
WO (1) WO2009140972A2 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5852433B2 (ja) * 2010-12-20 2016-02-03 株式会社ビー・エム・エル ソルチリンによる動脈硬化の判定方法
US9816090B2 (en) 2012-11-02 2017-11-14 The Brigham And Women's Hospital, Inc. Method for inhibiting calcification of a macrophage-derived matrix vesicle
WO2014071131A1 (en) * 2012-11-02 2014-05-08 The Brigham And Women's Hospital, Inc. Sortilin 1 is a novel inducer of vascular calcification
MX2015011462A (es) * 2013-03-14 2016-05-31 Jerome J Schentag Vesiculas colestosomicas para incorporacion de moleculas en quilomicrones.
WO2016164608A1 (en) * 2015-04-07 2016-10-13 Alector Llc Methods of screening for sortilin binding antagonists
WO2016164637A1 (en) 2015-04-07 2016-10-13 Alector Llc Anti-sortilin antibodies and methods of use thereof
CA3018859A1 (en) * 2017-12-01 2019-06-01 Turun Yliopisto Treatment of her2-dependent cancers by sorl1 inhibition
SI3618928T1 (sl) 2018-07-13 2023-04-28 Alector Llc Protitelesa proti sortilinu in postopki za uporabo le-teh
CN109580504B (zh) * 2018-10-19 2021-10-26 东软威特曼生物科技(南京)有限公司 一种脂蛋白胆固醇测定试剂及试剂盒
SE545408C2 (en) 2021-12-02 2023-09-05 Sortina Pharma Ab Sortilin inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4588580B2 (en) 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4904475A (en) 1985-05-03 1990-02-27 Alza Corporation Transdermal delivery of drugs from an aqueous reservoir
US4816258A (en) 1987-02-26 1989-03-28 Alza Corporation Transdermal contraceptive formulations
US4788062A (en) 1987-02-26 1988-11-29 Alza Corporation Transdermal administration of progesterone, estradiol esters, and mixtures thereof
US4927408A (en) 1988-10-03 1990-05-22 Alza Corporation Electrotransport transdermal system
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US8066997B2 (en) 2002-12-20 2011-11-29 Anders Nykjaer Modulation of activity of neurotrophins
EP1682170A2 (en) * 2003-11-07 2006-07-26 Lay Line Genomics SpA Compositions able to prevent neurodegenerative processes and methods of assaying the same
WO2006138343A2 (en) 2005-06-14 2006-12-28 Raptor Pharmaceutical Inc. Compositions comprising receptor - associated protein (rap) variants specific for lrp2 and uses thereof
JP2009508494A (ja) 2005-09-16 2009-03-05 ラプトール ファーマシューティカル インコーポレイテッド Ｃｒを含むタンパク質に対して特異的な受容体−結合タンパク質（ｒａｐ）変異体を含む組成物およびその使用
GB0611463D0 (en) 2006-06-09 2006-07-19 Novartis Ag Organic compounds
US20100028333A1 (en) * 2006-12-15 2010-02-04 Getty Krista L Receptor for amyloid beta and uses thereof
RS60019B1 (sr) 2006-12-21 2020-04-30 H Lundbeck As Modulacija aktivnosti proneurotrofina

Also Published As

Publication number Publication date
DK2282728T3 (da) 2015-04-20
EP2851084A1 (en) 2015-03-25
ES2533787T3 (es) 2015-04-14
EP2282728A2 (en) 2011-02-16
EP2282728B1 (en) 2015-02-25
EP2851084B1 (en) 2018-05-02
ES2680222T3 (es) 2018-09-05
US9084745B2 (en) 2015-07-21
US20150299304A1 (en) 2015-10-22
US20110166036A1 (en) 2011-07-07
HK1208802A1 (en) 2016-03-18
WO2009140972A2 (en) 2009-11-26
WO2009140972A3 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
DK2851084T3 (da) Modulation af Vps10p-domæne-receptorer til behandlingen af kardiovaskulær sygdom
US20170318057A1 (en) Modulation of the VPS10P-Domain Receptors for the Treatment of Cardiovascular Disease
EP2732823B1 (en) Modulation of the TrpV : Vps10p-domain receptor system for the treatment of pain
US9670263B2 (en) Modulation of the VPS10p-domain receptor family for the treatment of mental and behavioural disorders
CA2584048C (en) Multi-domain amphipathic helical peptides and methods of their use
US10172918B2 (en) SorCS1 for the treatment of obesity
US8936787B2 (en) Peptides promoting lipid efflux